Sanofi has entered into an exclusive global license agreement with Kali Therapeutics, a significant move that grants the pharmaceutical giant…
Read More
Monash University and ClinChoice Forge Strategic Alliance to Accelerate Therapeutic Development and Enhance Patient Access to Novel Treatments
Australia’s Monash University, a leading research institution, and ClinChoice, a global contract research organization (CRO), have formally announced a significant…
Read More
Gilead Sciences to Acquire Ouro Medicines for $2.2 Billion, Ushering in New Era of T-Cell Engagers in Autoimmune Diseases
Gilead Sciences is poised to make a significant entry into the burgeoning field of T-cell engagers (TCEs) with its $2.2…
Read More
Accelerated Pathways: A Strategic Approach to Fast-Track Qualifications in Today’s Dynamic Career Landscape
Before choosing a fast-track qualification, you should consider the workload, outcome, and more. The modern professional landscape is characterized by…
Read More
Opdivo Secures Landmark US and EU Approvals for Classical Hodgkin Lymphoma Across Pediatric and Adult Populations
Bristol Myers Squibb’s (BMS) groundbreaking immunotherapy, Opdivo (nivolumab), has achieved a significant milestone with dual approvals from the U.S. Food…
Read More
Macau Approves ImmunityBio’s Anktiva for Bladder Cancer, Marking First Asian Regulatory Milestone
ImmunityBio has achieved a significant regulatory victory with the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region, China,…
Read More
Artificial Intelligence Transforms Clinical Data Management, But Industry Adoption Lags Behind
The integration of artificial intelligence (AI) into clinical data management is ushering in a paradigm shift, moving Electronic Data Capture…
Read More
Earendil Labs Secures $787 Million to Accelerate AI-Driven Drug Discovery and Expand Robust Pipeline
Earendil Labs, a burgeoning biotechnology firm at the forefront of artificial intelligence (AI)-powered drug discovery, has announced a significant financial…
Read More
Johnson & Johnson’s Icotyde Poised to Challenge AbbVie’s Skyrizi in Plaque Psoriasis Market
The landscape of plaque psoriasis treatment is on the cusp of a significant shift with the U.S. Food and Drug…
Read More
Congruence secures $39.5m to advance small molecule correctors pipeline
Congruence Therapeutics, a pioneering biotechnology company focused on developing novel small molecule correctors, has successfully closed a significant $39.5 million…
Read More
